Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

"We feel included": education and inclusion of health care staff with minority language in elder care.

Krohne K, Døble B, Johannessen A, Thorsen K.

J Multidiscip Healthc. 2018 Dec 20;12:9-19. doi: 10.2147/JMDH.S178458. eCollection 2019.

2.

Multi-Centre Micro-Costing of Roux-En-Y Gastric Bypass, Sleeve Gastrectomy and Adjustable Gastric Banding Procedures for the Treatment of Severe, Complex Obesity.

Doble B, Welbourn R, Carter N, Byrne J, Rogers CA, Blazeby JM, Wordsworth S; By-Band-Sleeve Trial Management Group.

Obes Surg. 2019 Feb;29(2):474-484. doi: 10.1007/s11695-018-3553-9.

PMID:
30368646
3.

BMI1 is a therapeutic target in recurrent medulloblastoma.

Bakhshinyan D, Venugopal C, Adile AA, Garg N, Manoranjan B, Hallett R, Wang X, Mahendram S, Vora P, Vijayakumar T, Subapanditha M, Singh M, Kameda-Smith MM, Qazi M, McFarlane N, Mann A, Ajani OA, Yarascavitch B, Ramaswamy V, Farooq H, Morrissy S, Cao L, Sydorenko N, Baiazitov R, Du W, Sheedy J, Weetall M, Moon YC, Lee CS, Kwiecien JM, Delaney KH, Doble B, Cho YJ, Mitra S, Kaplan D, Taylor MD, Davis TW, Singh SK.

Oncogene. 2019 Mar;38(10):1702-1716. doi: 10.1038/s41388-018-0549-9. Epub 2018 Oct 22.

PMID:
30348991
4.

Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study.

Doble B, Pufulete M, Harris JM, Johnson T, Lasserson D, Reeves BC, Wordsworth S.

Health Qual Life Outcomes. 2018 Sep 20;16(1):191. doi: 10.1186/s12955-018-1019-3. Review.

5.

Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.

Woodcock F, Doble B; CANCER 2015 Consortium.

Med Decis Making. 2018 Nov;38(8):954-967. doi: 10.1177/0272989X18797588. Epub 2018 Sep 18.

PMID:
30226101
6.

Using "Big Data" in the Cost-Effectiveness Analysis of Next-Generation Sequencing Technologies: Challenges and Potential Solutions.

Wordsworth S, Doble B, Payne K, Buchanan J, Marshall DA, McCabe C, Regier DA.

Value Health. 2018 Sep;21(9):1048-1053. doi: 10.1016/j.jval.2018.06.016. Epub 2018 Aug 17.

PMID:
30224108
7.

Comment on: systematic assessment of decision analytic models for the cost-effectiveness of bariatric surgery for morbid obesity.

Doble B.

Surg Obes Relat Dis. 2018 Jul;14(7):1059-1061. doi: 10.1016/j.soard.2018.03.030. Epub 2018 Mar 31. No abstract available.

PMID:
29703504
8.

OTUD7A Regulates Neurodevelopmental Phenotypes in the 15q13.3 Microdeletion Syndrome.

Uddin M, Unda BK, Kwan V, Holzapfel NT, White SH, Chalil L, Woodbury-Smith M, Ho KS, Harward E, Murtaza N, Dave B, Pellecchia G, D'Abate L, Nalpathamkalam T, Lamoureux S, Wei J, Speevak M, Stavropoulos J, Hope KJ, Doble BW, Nielsen J, Wassman ER, Scherer SW, Singh KK.

Am J Hum Genet. 2018 Feb 1;102(2):278-295. doi: 10.1016/j.ajhg.2018.01.006.

9.

Clinical effectiveness and cost-effectiveness of issuing longer versus shorter duration (3-month vs. 28-day) prescriptions in patients with chronic conditions: systematic review and economic modelling.

Miani C, Martin A, Exley J, Doble B, Wilson E, Payne R, Avery A, Meads C, Kirtley A, Jones MM, King S.

Health Technol Assess. 2017 Dec;21(78):1-128. doi: 10.3310/hta21780.

10.

Prioritising the application of genomic medicine.

Doble B, Schofield DJ, Roscioli T, Mattick JS.

NPJ Genom Med. 2017 Nov 21;2:35. doi: 10.1038/s41525-017-0037-0. eCollection 2017. Review.

12.

A Single TCF Transcription Factor, Regardless of Its Activation Capacity, Is Sufficient for Effective Trilineage Differentiation of ESCs.

Moreira S, Polena E, Gordon V, Abdulla S, Mahendram S, Cao J, Blais A, Wood GA, Dvorkin-Gheva A, Doble BW.

Cell Rep. 2017 Sep 5;20(10):2424-2438. doi: 10.1016/j.celrep.2017.08.043.

13.

Economic Evaluation Alongside a Randomized Controlled Crossover Trial of Modified Group Cognitive-Behavioral Therapy for Anxiety Compared to Treatment-as-Usual in Adults With Asperger Syndrome.

Doble B, Langdon PE, Shepstone L, Murphy GH, Fowler D, Heavens D, Malovic A, Russell A, Rose A, Mullineaux L, Wilson ECF.

MDM Policy Pract. 2017 Aug 30;2(2):2381468317729353. doi: 10.1177/2381468317729353. eCollection 2017 Jul-Dec.

14.

Erratum to: What Are the Real Procedural Costs of Bariatric Surgery? A Systematic Literature Review of Published Cost Analyses.

Doble B, Wordsworth S, Rogers CA, Welbourn R, Byrne J, Blazeby JM; By-Band-Sleeve Trial Management Group.

Obes Surg. 2017 Aug;27(8):2193. doi: 10.1007/s11695-017-2768-5. No abstract available.

PMID:
28600617
15.

What Are the Real Procedural Costs of Bariatric Surgery? A Systematic Literature Review of Published Cost Analyses.

Doble B, Wordsworth S, Rogers CA, Welbourn R, Byrne J, Blazeby JM; By-Band-Sleeve Trial Management Group.

Obes Surg. 2017 Aug;27(8):2179-2192. doi: 10.1007/s11695-017-2749-8. Review. Erratum in: Obes Surg. 2017 Aug;27(8):2193.

16.

The impact of the Dementia ABC educational programme on competence in person-centred dementia care and job satisfaction of care staff.

Rokstad AMM, Døble BS, Engedal K, Kirkevold Ø, Benth JŠ, Selbaek G.

Int J Older People Nurs. 2017 Jun;12(2). doi: 10.1111/opn.12139. Epub 2016 Nov 20.

17.

Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L.

Lorgelly PK, Doble B, Rowen D, Brazier J; Cancer 2015 investigators.

Qual Life Res. 2017 May;26(5):1163-1176. doi: 10.1007/s11136-016-1443-y. Epub 2016 Nov 9.

18.

Budget impact and cost-effectiveness: can we afford precision medicine in oncology?

Doble B.

Scand J Clin Lab Invest Suppl. 2016;245:S6-S11. doi: 10.1080/00365513.2016.1206437. Epub 2016 Jul 18.

PMID:
27426412
19.

Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.

Doble B, John T, Thomas D, Fellowes A, Fox S, Lorgelly P.

Lung Cancer. 2017 May;107:22-35. doi: 10.1016/j.lungcan.2016.05.024. Epub 2016 Jun 2.

PMID:
27316470
20.

The promise of personalised medicine.

Doble B, Schofield DJ, Roscioli T, Mattick JS.

Lancet. 2016 Jan 30;387(10017):433-4. doi: 10.1016/S0140-6736(16)00176-8. No abstract available.

PMID:
26869572
21.

GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia.

Guezguez B, Almakadi M, Benoit YD, Shapovalova Z, Rahmig S, Fiebig-Comyn A, Casado FL, Tanasijevic B, Bresolin S, Masetti R, Doble BW, Bhatia M.

Cancer Cell. 2016 Jan 11;29(1):61-74. doi: 10.1016/j.ccell.2015.11.012.

22.

Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015.

Lorgelly PK, Doble B, Knott RJ; Cancer 2015 Investigators.

Pharmacoeconomics. 2016 Feb;34(2):139-54. doi: 10.1007/s40273-015-0343-2.

PMID:
26547307
23.

"Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic.

Parisot JP, Thorne H, Fellowes A, Doig K, Lucas M, McNeil JJ, Doble B, Dobrovic A, John T, James PA, Lipton L, Ashley D, Hayes T, McMurrick P, Richardson G, Lorgelly P, Fox SB, Thomas DM.

J Pers Med. 2015 Oct 29;5(4):354-69. doi: 10.3390/jpm5040354.

24.

Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.

Doble B, Lorgelly P.

Qual Life Res. 2016 Apr;25(4):891-911. doi: 10.1007/s11136-015-1116-2. Epub 2015 Sep 21.

PMID:
26391884
25.

Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.

Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi MA, McFarlane N, Subapanditha M, Nolte SM, Singh M, Bakhshinyan D, Garg N, Vijayakumar T, Lach B, Provias JP, Reddy K, Murty NK, Doble BW, Bhatia M, Hassell JA, Singh SK.

Clin Cancer Res. 2015 Dec 1;21(23):5324-37. doi: 10.1158/1078-0432.CCR-14-3147. Epub 2015 Jul 7.

26.

Fine-Tuning of the RIG-I-Like Receptor/Interferon Regulatory Factor 3-Dependent Antiviral Innate Immune Response by the Glycogen Synthase Kinase 3/β-Catenin Pathway.

Khan KA, Dô F, Marineau A, Doyon P, Clément JF, Woodgett JR, Doble BW, Servant MJ.

Mol Cell Biol. 2015 Sep 1;35(17):3029-43. doi: 10.1128/MCB.00344-15. Epub 2015 Jun 22.

27.

Glycogen synthase kinase-3 (Gsk-3) plays a fundamental role in maintaining DNA methylation at imprinted loci in mouse embryonic stem cells.

Meredith GD, D'Ippolito A, Dudas M, Zeidner LC, Hostetter L, Faulds K, Arnold TH, Popkie AP, Doble BW, Marnellos G, Adams C, Wang Y, Phiel CJ.

Mol Biol Cell. 2015 Jun 1;26(11):2139-50. doi: 10.1091/mbc.E15-01-0013. Epub 2015 Apr 1.

28.

Clinical players and healthcare payers: aligning perspectives on the cost-effectiveness of next-generation sequencing in oncology.

Doble B, Lorgelly P.

Per Med. 2015 Jan;12(1):9-12. doi: 10.2217/pme.14.81. No abstract available.

PMID:
29767540
29.

Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection?

Pullenayegum EM, Perampaladas K, Gaebel K, Doble B, Xie F.

Eur J Health Econ. 2015 Nov;16(8):847-55. doi: 10.1007/s10198-014-0633-1. Epub 2014 Sep 25. Review.

PMID:
25252970
30.

Gene Expression Profiling in Mouse Embryonic Stem Cells Reveals Glycogen Synthase Kinase-3-Dependent Targets of Phosphatidylinositol 3-Kinase and Wnt/β-Catenin Signaling Pathways.

Bartman CM, Egelston J, Kattula S, Zeidner LC, D'Ippolito A, Doble BW, Phiel CJ.

Front Endocrinol (Lausanne). 2014 Aug 13;5:133. doi: 10.3389/fendo.2014.00133. eCollection 2014.

31.

Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.

Doble B, Tan M, Harris A, Lorgelly P.

Expert Rev Mol Diagn. 2015 Feb;15(2):235-54. doi: 10.1586/14737159.2014.929499. Epub 2014 Aug 21. Review.

PMID:
25142227
32.

Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual.

Doble B, Harris A, Thomas DM, Fox S, Lorgelly P.

Pharmacogenomics. 2013 Sep;14(12):1405-17. doi: 10.2217/pgs.13.142.

PMID:
24024894
33.

The responses of neural stem cells to the level of GSK-3 depend on the tissue of origin.

Holowacz T, Alexson TO, Coles BL, Doble BW, Kelly KF, Woodgett JR, Van Der Kooy D.

Biol Open. 2013 Jun 20;2(8):812-21. doi: 10.1242/bio.20131941. eCollection 2013 Aug 15.

34.

Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence update.

Sehatzadeh S, Doble B, Xie F, Blackhouse G, Campbell K, Kaulback K, Chandra K, Goeree R.

Ont Health Technol Assess Ser. 2013 May 1;13(1):1-40. Print 2013. Review.

35.

Ectopic γ-catenin expression partially mimics the effects of stabilized β-catenin on embryonic stem cell differentiation.

Mahendram S, Kelly KF, Paez-Parent S, Mahmood S, Polena E, Cooney AJ, Doble BW.

PLoS One. 2013 May 27;8(5):e65320. doi: 10.1371/journal.pone.0065320. Print 2013.

36.

Comparing EQ-5D valuation studies: a systematic review and methodological reporting checklist.

Xie F, Gaebel K, Perampaladas K, Doble B, Pullenayegum E.

Med Decis Making. 2014 Jan;34(1):8-20. doi: 10.1177/0272989X13480852. Epub 2013 Mar 22. Review.

PMID:
23525701
37.

Reply to the editor.

Doble B, Xie F.

J Thorac Cardiovasc Surg. 2013 Feb;145(2):608-9. doi: 10.1016/j.jtcvs.2012.09.036. No abstract available.

38.

Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence-based Analysis (part B).

Sehatzadeh S, Doble B, Xie F, Blackhouse G, Campbell K, Kaulback K, Chandra K, Goeree R.

Ont Health Technol Assess Ser. 2012;12(14):1-62. Epub 2012 May 1. Review.

39.

Medulloblastoma stem cells: modeling tumor heterogeneity.

Manoranjan B, Venugopal C, McFarlane N, Doble BW, Dunn SE, Scheinemann K, Singh SK.

Cancer Lett. 2013 Sep 10;338(1):23-31. doi: 10.1016/j.canlet.2012.07.010. Epub 2012 Jul 14. Review.

PMID:
22796365
40.
41.

Medulloblastoma stem cells: where development and cancer cross pathways.

Manoranjan B, Venugopal C, McFarlane N, Doble BW, Dunn SE, Scheinemann K, Singh SK.

Pediatr Res. 2012 Apr;71(4 Pt 2):516-22. doi: 10.1038/pr.2011.62. Epub 2012 Feb 8. Review.

PMID:
22430388
42.

β-catenin enhances Oct-4 activity and reinforces pluripotency through a TCF-independent mechanism.

Kelly KF, Ng DY, Jayakumaran G, Wood GA, Koide H, Doble BW.

Cell Stem Cell. 2011 Feb 4;8(2):214-27. doi: 10.1016/j.stem.2010.12.010.

43.

Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials.

Salvo N, Doble B, Khan L, Amirthevasar G, Dennis K, Pasetka M, Deangelis C, Tsao M, Chow E.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):408-17. doi: 10.1016/j.ijrobp.2010.08.060. Epub 2010 Nov 13. Review.

PMID:
21075553
44.

Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci.

Popkie AP, Zeidner LC, Albrecht AM, D'Ippolito A, Eckardt S, Newsom DE, Groden J, Doble BW, Aronow B, McLaughlin KJ, White P, Phiel CJ.

J Biol Chem. 2010 Dec 31;285(53):41337-47. doi: 10.1074/jbc.M110.170704. Epub 2010 Nov 3.

45.

GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice.

Zhou J, Lal H, Chen X, Shang X, Song J, Li Y, Kerkela R, Doble BW, MacAulay K, DeCaul M, Koch WJ, Farber J, Woodgett J, Gao E, Force T.

J Clin Invest. 2010 Jul;120(7):2280-91. doi: 10.1172/JCI41407.

46.

Abnormalities in brain structure and behavior in GSK-3alpha mutant mice.

Kaidanovich-Beilin O, Lipina TV, Takao K, van Eede M, Hattori S, Laliberté C, Khan M, Okamoto K, Chambers JW, Fletcher PJ, MacAulay K, Doble BW, Henkelman M, Miyakawa T, Roder J, Woodgett JR.

Mol Brain. 2009 Nov 19;2:35. doi: 10.1186/1756-6606-2-35.

47.

GSK-3 is a master regulator of neural progenitor homeostasis.

Kim WY, Wang X, Wu Y, Doble BW, Patel S, Woodgett JR, Snider WD.

Nat Neurosci. 2009 Nov;12(11):1390-7. doi: 10.1038/nn.2408. Epub 2009 Oct 4.

48.

IL-17 receptor signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain.

Shen F, Li N, Gade P, Kalvakolanu DV, Weibley T, Doble B, Woodgett JR, Wood TD, Gaffen SL.

Sci Signal. 2009 Feb 24;2(59):ra8. doi: 10.1126/scisignal.2000066.

49.

Exploring pluripotency with chemical genetics.

Doble BW, Woodgett JR.

Cell Stem Cell. 2009 Feb 6;4(2):98-100. doi: 10.1016/j.stem.2009.01.005.

50.

Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation.

Kerkela R, Kockeritz L, Macaulay K, Zhou J, Doble BW, Beahm C, Greytak S, Woulfe K, Trivedi CM, Woodgett JR, Epstein JA, Force T, Huggins GS.

J Clin Invest. 2008 Nov;118(11):3609-18. doi: 10.1172/JCI36245. Epub 2008 Oct 1.

Supplemental Content

Support Center